MALY, J., S. DVORACKOVA, E. ZIMCIKOVA, A.A. KUBENA, J. KOLAR, J. VLCEK, Miroslav PENKA and K. MALA-LADOVA. Patterns in anticoagulant utilization in the Czech Republic during 2007-2017. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. DORDRECHT: SPRINGER, 2019, vol. 47, No 2, p. 305-311. ISSN 0929-5305. Available from: https://dx.doi.org/10.1007/s11239-019-01806-z.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Patterns in anticoagulant utilization in the Czech Republic during 2007-2017
Authors MALY, J. (203 Czech Republic), S. DVORACKOVA (203 Czech Republic), E. ZIMCIKOVA (203 Czech Republic), A.A. KUBENA (203 Czech Republic), J. KOLAR (203 Czech Republic), J. VLCEK (203 Czech Republic), Miroslav PENKA (203 Czech Republic, belonging to the institution) and K. MALA-LADOVA (203 Czech Republic).
Edition JOURNAL OF THROMBOSIS AND THROMBOLYSIS, DORDRECHT, SPRINGER, 2019, 0929-5305.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.054
RIV identification code RIV/00216224:14110/19:00113752
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s11239-019-01806-z
UT WoS 000459806100019
Keywords in English Anticoagulants; Drug utilization; Warfarin; DOAC; Czech Republic
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 11:22.
Abstract
Direct oral anticoagulants (DOACs) have gradually entered the Czech market as alternatives to vitamin K antagonists and parenteral anticoagulants since 2008. Considering the eventual changes, the aim was to evaluate drug use and expenditure patterns on anticoagulants in the Czech Republic. A retrospective utilization study was conducted retrieving data from the State Institute for Drug Control database, including reports on drug supplies from distributors with anatomical therapeutic chemical classification (ATC) codes B01AA, B01AB, B01AE, B01AF, and B01AX. The utilization on national level was expressed as the ratio of the number of defined daily doses per 1000 inhabitants per day (DDD/TID). Expenditures on all anticoagulants were also assessed. Data was analyzed using PASW (version 18.0). Between January 2007 and December 2017, the national anticoagulant utilization rate increased continuously from 14.15 to 27.67 DDD/TID. The use of DOACs was 0.002 DDD/TID in 2008, increased to 6.04 DDD/TID in 2017. Warfarin utilization, after a small decrease in 2008, has shown nearly stable levels in the recent years (70.9% of all anticoagulants; mean 11.55 DDD/TID over the last 5years), while its increase was halted by the spread of DOACs utilization (p<0.05). In 2017, over half of the expenditures (51.1%) were due to oral anticoagulants, whereof 47.6% was related to DOACs. The results reflected a growing utilization and increasing costs of all anticoagulants, especially in DOACs at the expense of warfarin. Still, additional information regarding patient persistence and prescribing patterns is needed for a better understanding of oral anticoagulant utilization.
PrintDisplayed: 31/5/2024 19:49